Filing search / Iovance Biotherapeutics, Inc. / "Long-term" / Page 4

8-K

EX-99.1

lnop6qw

6 Aug 20

Iovance Biotherapeutics Reports Second Quarter 2020 Financial Results

4:05pm

8-K

EX-10.2

300amkqkrw

9 Jun 20

Departure of Directors or Certain Officers

5:21pm

8-K

EX-1.1

n2hgin1689r3160 ogq

29 May 20

Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock

4:22pm

8-K

qmfs2cv to4jn

27 May 20

Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from

4:02pm

8-K

EX-99.1

xlyq0ce8c0t 8cfs0

27 May 20

Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from

4:02pm

8-K

EX-99.1

vtan21cflr7pc2

22 May 20

Investigating the Power of Tumor Infiltrating Lymphocytes for Treatment of Cancer May 2020

4:31pm

8-K

EX-99.1

ntt19e3n9 m56

5 May 20

Iovance Biotherapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update

4:30pm

8-K

EX-99.1

7gmxyszl6emnx0xhp

1 Aug 19

Iovance Biotherapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update

4:06pm

8-K

EX-99.1

eoz1g jgcbm

16 May 19

Iovance Biotherapeutics Announces Updates to Tumor Infiltrating Lymphocyte (TIL) Therapy Clinical Programs

5:20pm

8-K

EX-1.1

ewwg 49kk

12 Oct 18

Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock

4:06pm